StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.72−0.03 (-0.80%)

Close on Nov 18, 2026Market cap $283.83MP/E –Yield –

Fulcrum Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Fulcrum Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $80.00M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$80.00M+2752.0%
FY2023Dec 31, 2023$2.81M-55.8%
FY2022Dec 31, 2022$6.34M-66.9%
FY2021Dec 31, 2021$19.16M+117.2%
FY2020Dec 31, 2020$8.82M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0–
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$80.00M+8990.9%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$871.00K+27.2%
Q3 FY2023Sep 30, 2023$759.00K-35.8%
Q2 FY2023Jun 30, 2023$880.00K-53.2%
Q1 FY2023Mar 31, 2023$295.00K-88.6%
Q4 FY2022Dec 31, 2022$685.00K-94.0%
Q3 FY2022Sep 30, 2022$1.18M-76.0%
Q2 FY2022Jun 30, 2022$1.88M-57.0%
Q1 FY2022Mar 31, 2022$2.59M-45.9%
Q4 FY2021Dec 31, 2021$11.36M+168.9%
Q3 FY2021Sep 30, 2021$4.94M+167.0%
Q2 FY2021Jun 30, 2021$4.38M+119.1%
Q1 FY2021Mar 31, 2021$4.79M+538.5%
Q4 FY2020Dec 31, 2020$4.23M–
Q3 FY2020Sep 30, 2020$1.85M–
Q2 FY2020Jun 30, 2020$2.00M–
Q1 FY2020Mar 31, 2020$750.00K–

More Fulcrum Therapeutics figures

See a number that looks wrong?